Nitrates and Bone Turnover; Nitrates and Bone Turnover Bisphosphonate Sub-Study

Overview

Purpose: NABT: To compare five widely available nitrate formulations: (1) 15 of nitroglycerin (NTG) ointment, (2) 0.3 mg and (3) 0.6 mg of sublingual NTG, (4) 20 mg of isosorbide mononitrate (an oral tablet), and (5) 160 mg of glycerol trinitrate (a patch), for their efficacy on markers of bone formation and resorption and for the incidence and severity of headache they cause. Hypothesis: There is one ideal nitrate preparation which balances the clinical efficacy in bone remodeling against the common side effect of headache. NABT-B: To determine if nitrates affect markers of bone formation (serum BALP and P1NP) and resorption (serum CTX and urine NTX) in women who have recently discontinued treatment with alendronate, risedronate or zoledronate.

Full Title of Study: “Nitrates and Bone Turnover (NABT): Trial to Select the Best Nitrate Preparation”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2014

Interventions

  • Drug: Nitrates (NABT Main trial)
    • nitroglycerin; isosorbide mononitrate
  • Other: Placebo
    • Placebo ointment

Arms, Groups and Cohorts

  • Active Comparator: Nitrol
    • Nitroglycerin Ointment 2% USP
  • Active Comparator: Nitro-Dur
    • Nitroglycerin Extended Release Patch 160mg
  • Active Comparator: Nitrostat 1
    • Nitroglycerin 0.3mg Sublingual Tablet
  • Active Comparator: Nitrostat 2
    • Nitroglycerin 0.6mg Sublingual Tablet
  • Active Comparator: ISMO
    • Isosorbide Mononitrate 20mg Oral Tablet
  • Placebo Comparator: Placebo
    • Placebo Ointment

Clinical Trial Outcome Measures

Primary Measures

  • Bone Turnover Markers
    • Time Frame: 3 months
    • Markers of Bone Formation: Serum Procollagen type 1 amino- terminal propeptide (P1NP) Serum Osteocalcin (OC) Serum Bone-specific alkaline phosphatase (BALP) Markers of Bone Resorption: – Serum C-telopeptides of collagen cross-links (CTX)

Secondary Measures

  • Headache
    • Time Frame: Run-in phase – 2 days
    • Severity of headaches. Subjects recorded the severity of headaches upon awakening every day during the run-in phase using a visual analogue scale (VAS). The scale is represented by a line (continuum) 10 cm long. Subjects were asked to make a vertical line along the continuum to indicate the severity of their headache each morning upon awakening. The score is recorded in cm from “0” to “10”. A vertical line marked at “0” means no headache (score recorded = “0”), a vertical line marked at “10” means a terrible headache (score recorded = “10”).

Participating in This Clinical Trial

Inclusion Criteria

NABT:

  • Women aged 50 years and older whose last menstrual period occurred at least 3 years ago – Women without a uterus will be eligible after age 55 NABT-B: – Women aged 50 years and older whose last menstrual period occurred at least 3 years ago – Women without a uterus will be eligible after age 55 – Previously treated with alendronate but stopped within 2 years of study commencement; or previously treated with risedronate but stopped within 1 year of study commencement; or previously treated with zoledronate. Exclusion Criteria:

NABT:

  • A previous fracture of the hip, wrist, spine or ankle within the last 3 months; or a diagnosis of osteoporosis; – A history of bone disorders such as hyperparathyroidism or Paget's disease; – Treatment within 12 months of study entry with any agent that may influence bone metabolism including any hormone, anti-estrogen or raloxifene and prednisone (equivalent to 5 mg/d for 12 months or greater); – Treatment with any antiresorptive agent, including alendronate, risedronate, etidronate or denosumab use for at least four weeks within the last three years; – Previous treatment with intravenous zoledronate or parathyroid hormone; – Current treatment with nitrates; – A history of migraine headaches; – A history of angina or cardiovascular disease; – Inability to give informed consent; – Hypersensitivity to nitroglycerin. NABT-B: – A previous fracture of the hip, wrist, spine or ankle; or a self-reported diagnosis of osteoporosis; – A history of bone disorders such as hyperparathyroidism or Paget's disease; – Treatment within 12 months of study entry with any agent that may influence bone metabolism including any hormone, anti-estrogen or raloxifene and prednisone (equivalent to 5 mg/d for 12 months or greater); – Treatment with etidronate or denosumab use for at least four weeks within the last three years and any previous treatment with parathyroid hormone; – Current treatment with nitrates; – A history of migraine headaches; – A history of angina or cardiovascular disease; – Inability to give informed consent; – Hypersensitivity to nitroglycerin.

Gender Eligibility: Female

Minimum Age: 50 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Toronto
  • Collaborator
    • The Physicians’ Services Incorporated Foundation
  • Provider of Information About this Clinical Study
    • Principal Investigator: Sophie Jamal, Associate Professor/Endocrinologist – University of Toronto
  • Overall Official(s)
    • Sophie A Jamal, MD,PhD,FRCPC, Principal Investigator, Women’s College Research Institute/Women’s College Hospital

References

Jamal SA, Hamilton CJ, Eastell R, Cummings SR. Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial. JAMA. 2011 Feb 23;305(8):800-7. doi: 10.1001/jama.2011.176.

Jamal SA, Goltzman D, Hanley DA, Papaioannou A, Prior JC, Josse RG. Nitrate use and changes in bone mineral density: the Canadian Multicentre Osteoporosis Study. Osteoporos Int. 2009 May;20(5):737-44. doi: 10.1007/s00198-008-0727-7. Epub 2008 Sep 18.

Jamal SA, Cummings SR, Hawker GA. Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial. J Bone Miner Res. 2004 Sep;19(9):1512-7. doi: 10.1359/JBMR.040716. Epub 2004 Jul 26.

Jamal SA, Browner WS, Bauer DC, Cummings SR. Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res. 1998 Nov;13(11):1755-9. doi: 10.1359/jbmr.1998.13.11.1755.

Wimalawansa SJ, Grimes JP, Wilson AC, Hoover DR. Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss. J Clin Endocrinol Metab. 2009 Sep;94(9):3356-64. doi: 10.1210/jc.2008-2225. Epub 2009 Jun 23.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.